Edwards Lifesciences Corp (EW) VP Sells $966,515.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,500 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $175.73, for a total transaction of $966,515.00. Following the completion of the transaction, the vice president now directly owns 24,482 shares of the company’s stock, valued at approximately $4,302,221.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

EW opened at $178.02 on Friday. The firm has a market capitalization of $36.45 billion, a P/E ratio of 37.88, a P/E/G ratio of 2.26 and a beta of 0.90. Edwards Lifesciences Corp has a 12 month low of $123.00 and a 12 month high of $178.69. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, January 31st. The medical research company reported $1.17 EPS for the quarter, meeting the consensus estimate of $1.17. The business had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same period in the previous year, the firm posted $0.94 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corp will post 5.21 EPS for the current year.

Several brokerages have recently issued reports on EW. Raymond James boosted their price target on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “outperform” rating in a report on Thursday, December 6th. Citigroup boosted their price target on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a “sell” rating in a report on Wednesday, January 2nd. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $157.00 to $180.00 and gave the company an “overweight” rating in a report on Friday, December 7th. Canaccord Genuity boosted their price target on shares of Edwards Lifesciences from $177.00 to $186.00 and gave the company a “positive” rating in a report on Wednesday, January 16th. Finally, Stifel Nicolaus reissued a “positive” rating on shares of Edwards Lifesciences in a report on Thursday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $171.10.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cetera Advisor Networks LLC lifted its position in Edwards Lifesciences by 3.8% during the 4th quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after buying an additional 57 shares in the last quarter. Kentucky Retirement Systems lifted its position in Edwards Lifesciences by 0.7% during the 4th quarter. Kentucky Retirement Systems now owns 9,093 shares of the medical research company’s stock worth $1,393,000 after buying an additional 60 shares in the last quarter. Parallel Advisors LLC lifted its position in Edwards Lifesciences by 11.2% during the 4th quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock worth $101,000 after buying an additional 69 shares in the last quarter. BB&T Securities LLC lifted its position in Edwards Lifesciences by 0.9% during the 4th quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock worth $1,252,000 after buying an additional 70 shares in the last quarter. Finally, WealthPLAN Partners LLC lifted its position in Edwards Lifesciences by 2.0% during the 4th quarter. WealthPLAN Partners LLC now owns 3,575 shares of the medical research company’s stock worth $636,000 after buying an additional 70 shares in the last quarter. 83.29% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2019/03/15/edwards-lifesciences-corp-ew-vp-sells-966515-00-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: How to calculate compound interest

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit